Immune-mediated renal injury and cardiometabolic risk in IgA nephropathy: clinical evidence on telitacicept from a scoping review.
A targeted immune therapy may address both kidney damage and heart-metabolic risk in IgA nephropathy patients.
This scoping review examines the intersection of immune-mediated kidney injury and cardiovascular-metabolic risk in IgA nephropathy. It synthesizes evidence on telitacicept, a dual BAFF/APRIL inhibitor, as a treatment targeting both renal and cardiometabolic outcomes.
What the study was
- Study design
- Scoping review
- Population
- IgA nephropathy patients with cardiometabolic risk
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Frontiers in Nutrition
Why it surfaced
Indirect cardiometabolic relevance. Interesting intersection of nephrology and CV risk.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.